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ABSTRACT 
The overall aim of this work was to develop sustained release parenteral drug delivery system involving formation of an insitu 
sponge of anti-emetic drug typically co-administered in chemotherapy induced nausea and vomiting. The study involved 
formulation of the drug Granisetron Hydrochloride in a sponge forming gelatin matrix as a dry powder for reconstitution into a 
suspension to be injected into the body forming a sponge insitu intended to release the drug over a period of 5 days. The 
formulation was prepared by the method cryogelation and optimised using gelatin5% as a sponge forming polymer, crosslinking 
agent glutaraldehyde 0.3% , sustained release retardant Hydroxypropylmethyl cellulose K100M 1% (HPMC K100M) and 
suspending agent sodium carboxymethylcellulose 1% (NaCMC) to form a  solution intended to be administered subcutaneously. 
The formulation was evaluated for all prerequisites of parenteral and other parameters of gelatin matrix like swelling index, 
surface scanning microscopy for injectable suspension, sedimentation study, particle size, zeta measurement, in-vitro drug release, 
and stability studies. The formulation was found to sterile, isotonic, having swelling index 88% and SEM 100-120 μm, particle 
size 0.765μm.with zeta potential-14.2 mV, swelling time was 10 min. The in vitro drug release was found to be over 93.20% in 
Simulated Body fluid pH 7.4 at 37°C over a prolong period of 5days The formulation was physically and chemically stable at 
accelerated conditions for period of 1 month. 
Keywords: anti-emetic, gelatin matrix, cryogelation, injectable suspension 
 
INTRODUCTION: 
The Parenteral route is the most effective and common 
form of drug delivery system. It is used for which the 
bio-availability in limited by high first pass metabolism 
effect of other physicochemical limitation and for 
drugs with a narrow therapeutic index. Parenteral drug 
delivery has different technologies that can reduce the 
total number of injection throughout the drug therapy 
period. Sustained parenteral drug delivery began to 
emerge as a clearly designed sub-area of pharmaceutics 
in the middle of the twentieth century. Development of 
new sustained release injectable formulation has 
received considerable attention due to many 
advantages of these systems such as localized and site-
specific action, prolonged delivery period, decreased 
drug dosages, reduction of side effects and improved 
patient comfort and compliance over the conventional 
parenteral delivery .
1,2
 
Sustained release injectable formulations are basically 
designed as microparticles (microcapsules or 
microspheres), sponges, implants or gel systems. 
Microparticles are produced by complicated methods. 
They also suffer from several limitations such as low 
drug loadings, difficulty in particle size control due to 
aggregation and difficulty in their reconstitution to 
initial size. Efficiency of loading methods for active 
ingredients is limited and a high loading capacity is 
usually unattainable. A major limitation of implants is 
the requirement of surgery to remove the system which 
adds to their costs and risks. Due to these limitations 
and draw backs many researchers have proposed the 
use of injectable sponge formulations as substitutes.
3
 
Injectable sponge drug delivery system can entrap wide 
range of drugs and then release them into body over 
time. It is a unique technology for the novel release of 
injectable agents and consists of nano or micro porous 
beads loaded with active agent. After the creation of 
micro beds or matix, it gets compressed following the 
compression the sponge gets filled with active agent or 
medicine and injected into body. Following the 
injection, the sponge will expand to the original size 
and shape and start releasing drugs. Sponge or 
scaffolds have been developed using various 
techniques such as fiber bonding, gas foaming, 
microemulsion formation, phase separation, freeze-
drying, and porogen leaching. More recently, gelation 
at sub-zero temperatures, known as cryogelation, has 
been used to create sponge with large interconnected 
pores. During cryogelation, the reactants are restricted 
to the unfrozen/semifrozen phases and form a cross-
linked network upon polymerization, while the ice 
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crystals nucleated from the aqueous phase during 
freezing function as porogens. The melting of these ice 
crystals at temperature above the freezing temperature 
gives rise to interconnected macroporous networks. 
Injectable sponge drug delivery system which involves 
use of natural injectable polymers like chitosan, 
gelatin, sodium alginate, collagen etc.which act as a 
depot and release the drug in a timely fashion .
4, 5, 6 
Gelatin is a natural polymer which is biodegradable, 
nontoxic in nature. Due to its easy process ability and 
gelation properties, gelatin has been manufactured in a 
range of shapes including sponges, injectable hydrogels 
and gelatin microspheres etc. Gelatin sponges or 
matrices have been utilized for many regional drug 
delivery systems among the other forms of gelatin. 
Absorbable gelatin sponge (AGS) was introduced by 
Correl and Weisman as absorbable hemostatic agent in 
1945.
7
 
Granisetron hydrochloride (GH) is antiemetic drug, 
effective both intravenously and orally, acts by 
antagonizing 5HT3 receptor in the chemoreceptor 
trigger zone and probably in upper gastrointestinal 
tract. GH is used in management of nausea and 
vomiting induced by cytotoxic chemotherapy, 
radiotherapy and for the prevention of post operating 
nausea and vomiting. GH has 60% oral bioavailability 
due to hepatic first pass metabolism by 7 hydroxilation 
.Therefore it would be desirable to develop a sustained 
drug delivery system without this limitation of frequent 
administration. Recommended dose of GH is 2 mg/day 
twice a day before 30 min of chemotherapy induced 
nausea and vomiting for 5-7 days.
9
 
The present work was focused on formulation of an 
injectable sponge of Granisetron Hydrochloride in a 
gelatin matrix system intended for a 5-day sustained 
release to be administered in patients suffering from 
chemotherapy induced nausea and vomiting. 
MATERIALS 
Granisetron Hydrochloride was obtained as a generous 
gift from Wockhardt Research Center (Aurangabad, 
India). Gelatin was purchased from Lobachemie. 
(Mumbai, India). Glutaraldehyde was purchased from 
LobaChemie (Mumbai, India). HPMC K100M was 
purchased from Otto Chemie, Sodium CMC was 
purchased from LobaChemie (Mumbai, India). All 
other chemicals and reagents were of the analytical 
grade.  
METHODS 
Part A] Preparation and Evaluationof Gelatin 
matrix 
Preparation 
Gelatin was soaked in 100ml of water for 30 m to get 
solution at the varying concentration of 1-6% w/v of 
gelatin. The drug granisetron HCL (10mg) was added 
followed by addition of crosslinker glutaraldehyde 
(0.1-05 %) and then added sustained release polymer 
HPMC K100M (0.25-2%). This solution was then 
stirred vigorously for 10 m at 1000 rpm using overhead 
stirrer to form a firm foam. This foam was separated 
and spread on petri plates and further subjected to 
process of cryogelation. The process involved drying 
of gelatin matrix in deep freezer   at -10 to -12 ºC 
temperature for 24 h till it formed a dry porous matrix 
mass .This dry gelatin matrix mass was sifted through  
16 # to get fine brown coloured powder in aseptic 
condition. Optimised concentration of suspending 
agent sodium CMC (1%) was added, the powder was 
aseptically filled in previously sterilised amber 
coloured vials 2ml and then were subjected to 
sterilization by hot air oven at 140°C temperature for 2 
h.
4, 7
 
Optimization study 
A two factor, three levels full factorial design was 
employed for the optimization of Granisetron HCL 
gelatin matrix using Design-expert software
®
 9.0 (Stat-
Ease, Inc.,USA).The experimental design was applied 
to study the effect of independent factors such as 
gelatin concentration and glutaraldehyde concentration 
on dependent variables i.e. swelling index and pore 
size 
Table 1: Formulation combination as per the 3
2
 full 
factorial designs for Granisetron gelatin matrix. 
 
Evaluation of Gelatin matrix 
Appearance 
The appearance and physical characteristics of the 
gelatin matrix were checked by visual observation and 
using optical microscope microscopy.  
Drug Excipient Compatibility study 
The FTIR spectrum of pure drug and physical mixture 
in 1:1 ratio were recorded on spectrophotometer for 
interaction between them by using KBr pellet method. 
Swelling Index 
Swelling index was determined by soaking pre-
weighed pieces (1 x 1 cm) of gelatin matrices in double 
distilled water. Soaked matrices were removed with 
blunt forceps and blotted to remove excess liquid from 
the medium at predetermined time (5, 10, 15 m) and 
their weight was determined by using digital weighing 
balance and % swelling index was calculated by the 
following equation.
4,5
 
                          % S =    W2 – W1    ×100 
      W1 
Formulatio Code Gelatin % w/v GLU (% v/v) 
F1 6 0.1 
F2 5 0.1 
F3 4 0.5 
F4 4 0.3 
F5 4 0.1 
F6 5 0.3 
F7 6 0.3 
F8 6 0.5 
F9 5 0.5 
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Where, S is the percentage water adsorption of gelatin 
matrices at equilibrium. 
W1 is the initial weight of the gelatin matrix. 
W2 is the after immersion weight of the gelatin matrix. 
Surface scanning study 
Morphological analysis was carried out by a scanning 
electron microscope (SEM) JEOL model JSM-
6390LV. Surface morphology of gelatin matrix can be 
observed by using SEM. Gelatin matrix was mounted 
on aluminium pin stubs using conductive self-adhesive 
carbon label. 
7 
Part B] Preparation and Characterization of 
Injectable suspension 
Preparation 
Injectable suspension was prepared by reconstitution of 
formulation. Dry gelatin matrix powder was 
reconstituted in 2ml of sterile water for injection 
(SWFI) at the time of administration to form an 
injectable suspension. 
Evaluation of Injectable suspension 
Appearance and pH 
The appearance of formulation was checked by visual 
observation and pH of injectable suspension was 
measured using pH meter which was previously 
calibrated using standard buffers of pH 4 & pH 7. 
Syringeability 
Syringeability of the formulation was assured using 21 
to 26 G needles. It was important to assure 
syringeability of formulation prior to animal study. All 
prepared formulations were withdrawn into identical 5 
ml plastic syringes placed with 21 to 26 gauge needles 
to a constant volume (1 ml). The solutions which were 
easily passed from a particular syringe were termed as 
pass and the ones which were difficult to pass were 
termed as fail.
8, 10
 
Sedimentation Volume 
In sedimentation study, the suspension was transferred 
to a stoppered measuring cylinder and was stored at 
room temperature for 24 h. The volume of sediment 
formed was noted at regular interval of time (1, 3, 5, 8 
h). 
8, 10 
 
 Sedimentation volume    =        final volume (Vu) 
                                               Original volume (VO) 
Swelling Time 
Swelling time was observed visually for gelatin matrix. 
Dry gelatin matrix powder was added in 2ml Simulated 
body fluid (PH 7.2) Time required to swell was 
determined. 
Particle Size and Zeta Potential Measurements 
Formulation was suspended in water and sonicated to 
form a smooth and uniform dispersion. The particle 
size and zeta potential of the formulation was obtained 
using a Malvern particle size analyzer (Mastersizer-
2000, UK) .
4, 8
 
Drug content estimation 
0.25 ml of the test formulation was diluted with excess 
of methanol and evaporated to dryness. The residue 
was diluted up to 100 ml with mobile phase to get a 
stock solution of 100µg/ml. From this stock solution, a 
solution of 40 µg/ml was prepared and analysed by 
HPLC. 
14
 
Sterility Testing 
Sterility testing was carried out as per the IP 2014. The 
formulation was incubated for not less than 14 days at 
30°-35°C in the alternate fluid thioglycolate medium to 
find the growth of bacteria & at 20°-25°c in Soya bean 
casein digest medium to find the growth of fungi in 
formulation. The test was performed using positive and 
negative controls. The bacterial strain used for positive 
control was Clostridium sporogenes whereas the fungal 
strain was Candida albicans
15
 
In-vitro Drug Release Studies 
In vitro release studies of Granisetron HCL from 
Injectable gelatin suspension system was performed at 
37 ˚C using membraneless dissolution model. The 
dissolution medium was simulated body fluid pH 7.2. 1 
ml of dissolution medium was withdrawn at specific 
time intervals and replenished with fresh medium to 
maintain sink conditions. Orbital shaking Incubator 
was used to maintain the temperature at 37 ˚C and 
agitated for 30 rpm. Aliquots withdrawn were suitably 
diluted and analyzed using UV spectrophotometer at 
302nm.
11
 
Accelerated Stability study   
Stability studies were carried out on optimized 
formulation according to International Conference on 
Harmonization (ICH) guidelines. Formulations were 
filled in vials and subjected to room temperature i.e. at 
25°C ± 2°C/60% ± 5% RH and 40°C ± 2°C/75% RH ± 
5% RH for 1 month. Samples were analysed for 
appearance, pH and in vitro drug release.
16
 
RESULTS AND DISCUSSIONS 
Optimization study 
The design of experiment (DOE) is an approach in 
which process variables are first screened and then 
optimized to determine best settings for the variables. 
Full factorial design is a quadratic design which 
requires 3 levels for each factoras. 
From the all batches F6 batch was selected that attained 
the desired swelling index i.e. 88 % and pore size was 
found to be 11.9 um and was further evaluated. The 
results of the each experiments performed as per the 
software are given in Table 2. Empirical relationships 
between the response and the independent variables 
have been expressed by the following quadratic 
model.
13
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Table 2: Formulation combination as per the 3
2
 full 
factorial design with responce 
 
Response Surface plots 
 
Figure 1: Response surface of swelling index 
 
Swelling Index=+84.33+8.33* A+1.00* B+0.25* AB -
18.00 * A^2 
Where, A is concentration of gelatin and B is 
Concentration of glutaraldehyde. 
Swelling index is the capacity of swelling in body. It is 
important parameter in injectable sponge preparation 
and it depends on polymer concentration i.e. gelatin 
and crosslinking agent i.e. glutaraldehyde. 
As shown in figure1 upon increase in concentration of 
gelatin and glutaraldehyde there is increase in swelling 
index. It was found that with increase in concentration 
of gelatin from 4% to 5% and of glutaraldehyde 0.1 to 
0.3 % swelling index increases but at concentration 
beyond 5 % to 6% of gelatin and 0.3% of 
glutaraldehyde highly viscous solutions are formed 
which is difficult to stir and formulate into foam. 
 
Figure 2: Response surface of pore size 
Pore size =+10.99+0.57* A +2.05* B+1.13* 
AB+2.23* A^2-2.78* B^2 
Where, A is concentration of gelatin and B is 
Concentration of glutataldehyde.  
Glutaraldehyde is a crosslinker which mainly 
contributes to form a porous matrix of gelatin once it 
swells in fluid. It was found (figure 2) that with 
increase in concentration of gelatin from 4% to 5% and 
of glutaraldehyde from 0.1 to 0.3 %, pore size 
increases but at concentration beyond 5 % to 6% of 
gelatin and of 0.3% of glutaraldehyde highly viscous 
solutions is formed which is difficult to stir and 
formulate into a foam therefore there was also a 
decrease in pore size. Thus as per optimization study 
0.3% concentration of glutaraldehyde gives higher pore 
size. 
Contribution of concentration of polymer and 
crosslinking agent has effect on both the parameters i.e. 
swelling index andpore size. As the matrix swells in 
the media it forms porous sponge. The pore size of the 
sponge entraps the drug and slowly releases the drug.  
Thus 5% of gelatin concentration and 0.3% 
Concentration of glutataldehyde was selected for 
further study that gave maximum swelling and pore 
size of the sponge. 
 
Table 3: Desirability function of optimized formulation 
Formulation Code Gelatin Concentration 
(% w/v) 
Glutaraldehyde 
Concentration. (% v/v) 
Desirability 
F 6 5 0.3 0.9762 
 
The release is prolonged over the predetermined time 
period depending upon the concentration of the release 
retardant HPMC K100M added. 
The quality of the fitted model was expressed by the 
coefficient of determination R
2
, and its statistical 
significance was checked by an F-test (analysis of 
variance) at the 5% significance level. The statistical 
Formulation 
Code 
Swelling Index 
(%) 
Pore size 
(μm) 
F1 68 5.7 
F2 78 8.7 
F3 60 5.6 
F4 58 3.2 
F5 50 4.3 
F6 88 11.9 
F7 71 2.5 
F8 73 4.7 
F9 75 9.7 
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significance of the regression coefficients was 
determined by using the t-test (only significant 
coefficients with p-value < 0.05 are included). The 
optimum processing conditions were obtained by using 
graphical and numerical analysis based on the criteria 
of the desirability function and the response surface. 
 
Table 4: ANOVA test result 
SOURCE ABSORBANCE 
F-value P-value R-square 
Quadratic model 11.61 0.0001 0.9508 
 
PART A] Evaluation of Gelatin Matrix 
Appearance  
All the formulations were brown colour, brittle matrix powder in appearance. Dry heat sterilization had no effect on 
physical and chemical properties of the formulation. 
Drug Excipient Compatibility study 
 
 
Figure 3: FT-IR Spectra of A) Drug B) Drug + Gelatin C) Drug + HPMCK100M and D) formulation of 
Granisetron HCL 
 
The FTIR spectrum of pure drug and physical mixture 
in 1:1 ratio were recorded on spectrophotometer and it 
shows no any significant change in functional group 
peak i.e. there was no major interaction between drug 
and excipients. The characteristic IR absorption peaks 
of Granisetron HCL and other excipients were at 720-
780cm
-1
(C-H stretch), 2410-2550cm
-1
(C-H=0), 1650-
1580cm
-1
(N-H bend), 3400-3200cm
-1
(N-H stretch) 
present as shown in (figure 3) .FTIR spectra of the 
formulation with polymers showed all the Granisetron 
HCL characteristics absorption bands suggesting there 
is no chemical interactions between the drug and 
polymers used in the formulation.
14 
Swelling Index 
The prepared matrices were subjected to swelling 
Index which ranged from 50 % to 88 %.Swelling 
index of optimized F6 batch was found to be 88%. It 
represents the capacity of swelling of matrix in blood. 
In body gelatin matrix absorbs  blood or body fluid 
and it opens the pores of matrix to gives sustained 
release of drug over 5 days period. As shown in fig 
5% gelatin concentration has higher swelling property 
and also gives higher sustained to release of drug. 
 
Figure 4: Effect of concentration of polymer on 
swelling index 
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Scanning electron Microscopy  
Scanning electron Microscopy is used to study the 
microscopic aspects of the formulation. The Gelatin 
matrix appeared as a very porous and rough structure. 
The pore size was in the range of 100-120 μm. 
Morphology of gelatin sponge is shown in figure 5. 
 
Figure 5: Scanning electron Microscopy of gelatin 
matrix 
B] Evaluation of Injectable suspension- 
Appearance and pH 
All the formulations were dispersed suspension 
system. The pH of the all the formulations was found 
to be between 6.5-7. The pH values were found to be 
in the range tolerated by the subcutaneous tissue. 
Moreover, the drug was found to be most stable in this 
pH range. 
Syringeability 
The formulation easily passed through the needle 
gauge 21. This needle size is suitable for 
subcutaneous injection. 
Table 5: Syringeability of optimized formulation 
Needle gauge no. Result 
21 Pass 
22 Fail 
24 Fail 
26 Fail 
 
Sedimentation study 
The sedimentation volume can have values ranging 
from less than 1.The sedimentation volume was found 
to be constant 0.075 for a period of 15 min. The 
ultimate height of the solid phase depends on the 
concentration of solid and the particle size. 
Table 6: Sedimentation study of gelatin matrix 
powder 
TIME Sedimentation volume 
5 min 0.050 
10 min. 0.075 
15 min 0.075 
 
Swelling time 
Swelling time of gelatine matrix was 10 m. It is time 
required to swell after injecting the reconstituted 
powder in sterile water for injection and thus 
formation of sponge in-situ 
Particle Size and Zeta Potential Measurements 
Particle size of gelatin suspension  was found to 
be0.7654 um(765.4 d.nm) and Pdl was 0.665. gelatin 
suspension has good particle size that indicates 
formulation will easily administered  in body and  
easily passed through blood vessels. 
Zeta potential is a measure of surface charge. Zeta 
potential of formulation was  -14.2 Mv thatmeans 
gelatin suspension  has good physical stability. Zeta 
Potential determinations can be great value in the 
development of suspensions, particularly if the 
controlled flocculation approach is used to formulate. 
 
Figure 6: Partic1e Size of gelatin suspension. 
 
Figure 7: Zeta potential of gelatin suspension. 
Drug content estimation 
The percentage drug content in the formulation was 
calculated and found to be 95.54 % indicating 
insignificant loss of drug during the formulation. 
Sterility testing 
No turbidity was observed in test samples after 14 
days. The formulation was found to be free from 
bacteria and fungi. Hence, it passes the test for 
sterility as per I.P. The sterility of the formulation 
may be attributed to aseptic process of preparation 
and filling the amber colour vials and dry heat 
sterilization at 140°C temperature for 2 h. 
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Table 7: Observations for bacterial growth 
Sample Observation 
Positive control Growth 
Negative control No growth 
Test sample No growth 
  
Table 8: Observations for fungal growth 
Sample Observation 
Positive control Growth 
Negative control No growth 
Test sample No growth 
 
In-vitro Drug Release Studies 
In vitro drug release study serve as a comparative tool 
in formulation and development. Drug release from 
gelatin matrix into release medium was regulated by 
dissolution or diffusion of drug, depending upon 
experimental conditions. In vitro drug release of 
gelatin matrix formulation was regulated by diffusion 
mechanism. As the concentration of HPMC K100M 
increases drug release was retarded. The release on 
subsequent days was at par with the expected values. 
About 93.20 % of drug release was observed on the 
last day which indicated sustenance of the release for 
5 days 
 
Table 9: In-vitro Drug Release of formulation 
 
 
 
Figure 8: In vitro release profile for optimized 
formulation 
 
Table 10: Model for release kinetics 
Formulation F6 Zero order First order Korsemeyer-
Peppas order 
Higuchi order 
R
2
 0.972 0.893 0.984 0.975 
 
 
It is evident from above data (Table 10) that 
Korsmeyer peppas model was the best fit model for 
optimized batch. It indicates that the optimized 
formulation followed non-Fickian diffusion mechanism 
for drug release. 
Accelerated stability study 
Stability studies indicates that formulation F6 was 
physically and chemically stable at ambient 
temperature i.e at 25°C ± 2°C/60% RH ± 5% RH  and 
at accelerated conditions 40°C ± 2°C/75% RH ± 5% 
RH for a period of 1 month. From stability studies it 
was observed that the formulation of Granisetron HCL 
was stable at selected storage conditions in amber 
coloured vials. It shows no change in appearance, 
colour, pH, with negligible decrease in vitro drug 
release. 
 
Table 10: Stability studies results after 1 month 
Time(days) Cumulative  % Drug release 
1 18.50 
2 38.35 
3 57.20 
4 76.23 
5 93.20 
 
Formulation 
code 
 
Storage condition 
Appearance, colour, pH In vitro drug 
Release (%) 
after 1 month 
Before Reconstitution 
of gelatin matrix 
After Reconstitution 
of gelatin matrix 
F6 Room temperature(25°C ± 
2°C/60% RH ± 5% 
Brown powder Dispersed 
suspension, 6.4 
92.97 
Accelerated temperature(40°C 
± 2°C/75% RH ± 5% RH) 
Brown powder,6.3 Dispersed 
suspension, 6.2 
 
90.34 
Mirajkar et al                                     Journal of Drug Delivery & Therapeutics. 2016; 6(4):55-62                                62 
© 2011-16, JDDT. All Rights Reserved                                   ISSN: 2250-1177                                  CODEN (USA): JDDTAO 
 
Figure 9: In vitro release after 1 month 
 
CONCLUSION 
The present work was based on the need to reduce the 
frequency of administration of Granisetron 
Hydrochloride. It can be concluded that sustained-
release parenteral formulations are helpful in increasing 
the efficiency of the dose as well as improving the 
patient’s compliance. Sustained release injectable 
gelatin sponge formulation Granisetron Hydrochloride 
of would be advantageous over the prevailing tablets 
and injections, that require administration every for 12 
for 5 days regimen. Injectable gelatin sponge 
formulations can be anticipated as a promising 
alternative to conventional oral and parenteral dosage 
forms. Thus makes easing the practice of medication 
with an objective to save the valuable life of human 
being. 
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